io9 published data in the Journal of Clinical Oncology today demonstrating that its AI biomarker platform OncoGaze identified HRD-positive patients from routine tissue slides
CEO Greg Hamilton describes how patients who were diagnosed with this software platform had better outcomes, how it might increase the treatable patient population, and next steps towards applying for approval as a companion diagnostic for PARP inhibitors.